Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of TQB2102 Injection in Patients With Advanced Cancers

NCT05735496 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05735496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05735496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of TQB2102 Injection in Patients With Advanced Cancers
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 9, 2023
Completion date
July 31, 2027
Enrollment
219 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer